Home > For Consumers > Second‐generation antipsychotic drugs...
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2003-.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet].

Second‐generation antipsychotic drugs for anxiety disorders 

This version published: 2012; Review content assessed as up-to-date: November 10, 2010.

Plain language summary

Anxiety disorders are a prevalent and disabling condition. Because of high rates of treatment resistance, there is interest in new pharmacological treatment options such as second‐generation antipsychotics. This systematic review evaluated the efficacy and tolerability of second‐generation antipsychotics in the treatment of anxiety disorders. We found eleven randomised placebo‐controlled trials, comparing quetiapine, olanzapine and risperidone with placebo and antidepressants. The vast majority of the available data was on quetiapine (> 3000 participants). Participants with generalised anxiety disorder responded significantly better to quetiapine than to placebo, measured as a reduction in the Hamilton Anxiety Scale (HAM‐A). Participants treated with quetiapine were more likely to drop out due to adverse events, to gain weight, to suffer from sedation or to suffer from extrapyramidal side effects. The evidence on the other second‐generation antipsychotics is currently too limited to draw any conclusions.

Abstract

Background: Anxiety disorders are common and disabling conditions, with a lifetime prevalence of 17% in the general population. Due to high rates of treatment resistance, there is interest in new pharmacological treatment options such as second‐generation antipsychotics.

Objectives: To evaluate the efficacy and tolerability of second‐generation antipsychotics as monotherapy or adjunctive treatment for people with anxiety disorders.

Search methods: The Cochrane Depression, Anxiety and Neurosis Group's controlled trial registers (CCDANCTR‐Studies and CCDANCTR‐References) were searched up to 21 July 2010. The author team ran complementary searches on ClinicalTrials.gov.

Selection criteria: We included all randomised trials (RCTs) comparing second‐generation antipsychotic drugs with placebo, benzodiazepines, pregabalin or antidepressants. Participants were people with generalised anxiety disorder, panic disorder and specific phobias including social phobia.

Data collection and analysis: Two authors extracted data independently. For dichotomous data we calculated odds ratios (OR) and their 95% confidence intervals (CI). For continuous data we calculated mean differences (MD) based on a random‐effects model.

Main results: The review currently includes eleven RCTs with 4144 participants on three second‐generation antipsychotics (olanzapine, quetiapine, risperidone). Nine studies investigated the effects of second‐generation antipsychotics in generalised anxiety disorder, only two studies investigated the effects in social phobia. There were no studies on panic disorder or any other primary anxiety disorder.

Seven studies investigated the effects of quetiapine. Participants with generalised anxiety disorder responded significantly better to quetiapine than to placebo (4 RCTs, N = 2265, OR = 2.21, 95% CI 1.10 to 4.45). However, they were more likely to drop out due to adverse events, to gain weight, to suffer from sedation or to suffer from extrapyramidal side effects. When quetiapine was compared with antidepressants, there was no significant difference in efficacy‐related outcomes, but more participants in the quetiapine groups dropped out due to adverse events, gained weight and feeling sedated. Only two very small studies with a total of 36 participants examined olanzapine and found no difference in response to treatment. Two trials compared adjunctive treatment with risperidone with placebo and found no difference in response to treatment.

Authors' conclusions: We identified eligible trials on quetiapine, risperidone and olanzapine. The available data on olanzapine and risperidone are too limited to draw any conclusions. Monotherapy with quetiapine seems to be efficacious in reducing symptoms of generalised anxiety disorder and this effect may be similar to that of antidepressants. However, quetiapine's efficacy must be weighed against its lower tolerability.

Editorial Group: Cochrane Depression, Anxiety and Neurosis Group.

Publication status: Edited (no change to conclusions), comment added to review.

Citation: Depping AM, Komossa K, Kissling W, Leucht S. Second‐generation antipsychotics for anxiety disorders. Cochrane Database of Systematic Reviews 2010, Issue 12. Art. No.: CD008120. DOI: 10.1002/14651858.CD008120.pub2. Link to Cochrane Library. [PubMed: 21154392]

Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...